Low-dose radiotherapy followed by chemoimmunotherapy in neoadjuvant treatment of locally advanced esophageal squamous cell carcinoma: A phase II STIMULATION-01 clinical trial.

This is a Human Clinical Trial study.

View at Publisher

Ask AI

Bookmark

Share

Key Points

The research aims to evaluate the effectiveness of neoadjuvant low-dose radiotherapy combined with chemoimmunotherapy in esophageal squamous cell carcinoma.
Phase II clinical trial with 30 patients diagnosed with esophageal squamous cell carcinoma
Inclusion criteria included histologically confirmed disease at specific clinical stages
Patients received two cycles of low-dose radiotherapy followed by nab-paclitaxel and carboplatin, with varying doses and frequencies.
pCR rate for the 8Gy/4f group was 70%, significantly higher than the 4Gy/2f group at 10% (p = 0.011)
ctDNA clearance rates were numerically higher in the 8Gy/4f and 6Gy/3f groups compared to 4Gy/2f but not statistically significant
23 out of 30 patients experienced treatment-related adverse events, mostly mild.

We only have this paper's title and publication details.

Answers are grounded in this paper and cite their sources.

Phase II trial shows neoadjuvant treatment improves pCR rates in esophageal cancer, suggesting effective strategies for enhancing immunotherapy.

No takes yet. Share an insight, caveat, or question.

Yuan et al. (2026) studied this question.

View at Publisher

Ask AI

Bookmark

Share